TY - THES A1 - Gschmack, Eva Maria T1 - Anti-Gehirn-Autoantikörper und deren Bedeutung bei Morbus Parkinson T1 - Anti-brain-Autoantibodies and their role in Parkinson's Disease N2 - Hintergrund: Die der Pathogenese von Morbus Parkinson (PD, Parkinson’s disease) zugrunde liegenden Mechanismen sind bis heute nur unvollständig verstanden. Insbesondere ist unklar, durch welche ursächlichen Faktoren Parkinson ausgelöst wird. Bei der HIV-Infektion treten bei vielen Patienten neurologische Störungen auf (HIV-Associated Neurological Disorders, HAND), die in der klinischen Symptomatik und der Lokalisation der betroffenen Gehirnareale dem Morbus Parkinson ähneln. Möglicherweise könnte eine Fehlregulation der Immunantwort eine Rolle als Auslöser beider Erkrankungen spielen. In dieser Arbeit wurde die Autoimmunantwort von PD- und HAND-Patienten und gesunden Kontrollen gegen verschiedene Gehirnhomogenate untersucht, die während der Parkinsonerkrankung in unterschiedlichem Ausmaß geschädigt werden. Das Autoimmun-Signal wurde quantifiziert und prominente Autoantigene wurden identifiziert. Methoden: In dieser Arbeit wurde ein Western-Blot-basiertes Verfahren zum Nachweis von Autoantikörpern gegen Gehirngewebe entwickelt. Dieses Verfahren wurde nach Optimierung mit Plasmaproben von gesunden Kontrollen, PD-Patienten und Patienten mit HIV-Infektion insbesondere an einer Gruppe von 40 Parkinson-Patienten (Durchschnittsalter 65 Jahre, 45 % weiblich) und 40 alters- und geschlechtsgemachten Kontrollen (Durchschnittsalter 62 Jahre, 50 % weiblich) angewendet und die humorale Autoimmunität gegen verschiedene Gehirnareale untersucht. Dazu wurden die verschiedenen Areale (dorsaler Motornucleus des Glossopharynx- und Vagusnervs (dm), Substantia nigra (SN), anteromedialer temporaler Mesocortex (MC), high order sensorische Assoziations- und präfrontale Felder (HC), first oder sensorische Assoziations- und prämotorische Felder, primäre sensorische und motorische Felder (FC)) von post-mortem Gehirnen homogenisiert, auf SDS-Gradienten-Gelen elektrophoretisch aufgetrennt und auf Nitrocellulose geblottet. Die Membranen wurden mit den Plasmen inkubiert und gebundene Autoantikörper immunologisch detektiert. Die Signale wurden qualitativ und quantitativ ausgewertet. Mit Hilfe einer zweidimensionalen Elektrophorese und anschließender Immunfärbung wurden prominente Autoantigene durch Massenspektroskopie identifiziert. Ergebnisse: Mit dem in dieser Arbeit entwickelten Assay lässt sich die humorale Autoimmunantwort gegen Gehirngewebe semiquantitativ bestimmen. In allen untersuchten Proben konnten verschiedene Autoantikörper gegen unterschiedliche Antigene nachgewiesen werden. Der Gesamt-IgG-Gehalt der Plasmen unterscheidet sich weder zwischen PD-Patienten und gesunden Kontrollen, noch zwischen Männern und Frauen signifikant. Weibliche PD-Patienten zeigen signifikant stärkere Signale gegen dm als männliche (p = 0.02, Mann-Whitney-U-Test), der wiederum in jedem Patienten - unabhängig vom Geschlecht - von den untersuchten Hirnarealen signifikant stärker autoimmunologisch erkannt wird, als die übrigen Hirnareale (p < 0.0001, Friedman-ANOVA). In jedem Hirnareal wurden drei Banden besonders häufig erkannt (45, 40 und 37 kDa), jede davon am stärksten im dm (p < 0.0001, Friedman-ANOVA). Die Einzelanalysen der Signalintensitäten zeigt, dass PD-Patienten signifikant weniger Autoreaktivität gegen die 45 kDa-Bande in der SN (p = 0.056), im MC (p = 0.0277) und im FC (p = 0.0188) zeigen, als Kontrollen. Weitere Analysen zeigen, dass männliche PD-Patienten hochsignifikant weniger das 45 kDa-Protein im SN (p < 0.0001), MC (p = 0.0042) und FC (p = 0.0088) erkennen als Kontrollen, wohingegen bei den weiblichen Kontroll- und PD-Plasmen kein Unterschied festzustellen war. Ein weiteres Protein bei 160 kDa wird signifikant unterschiedlich stark in allen Gehirnarealen erkannt (p < 0.0001, Friedman-ANOVA), wobei die stärkste Immunreaktivität gegen FC besteht. Basierend auf dem Nachweis der 45 kDa-Bande aus der SN ergibt sich eine Odds Ratio für das Merkmal Parkinson von 3.38 (CI 1.11 – 10.30). Bei Männern ist diese Odds Ratio sogar 53.12 (CI 2.79 - 1012), bei Frauen 0.44 (CI 0.09 – 2.09). Die Sensitivität dieses Tests liegt bei Männern bei 1 (CI 0.84 – 1), die Spezifität bei 4.41 (0.31 – 0.78). Die negativ prädiktiven Werte liegen in allen Gruppen über 99.15 %. Die Identifizierung der Proteine mittels Massenspektroskopie ergab, dass es sich bei den 37 – 45 kDa Banden um Isoformen oder posttranslational modifizierte Formen des GFAP (glial fibrillary acidic protein), einem Bestandteil von Neurofilamenten v.a. in Astrozyten handelt. Außerdem wurde Fructose-Bisphosphate Aldolase A und Aspartat-Aminotransferase (mitochondriale Isoform 1 Vorläufer), beides Proteine des Kohlenhydrat-Stoffwechsels und der Glykolyse, als weitere Proteine mit ebenfalls 45 kDa identifiziert. Bei dem identifizierten Protein mit dem Molekulargewicht von 160 kDa handelt es sich wahrscheinlich um Dihydropyrimidinase-related protein 2, wie GFAP ebenfalls bei der Bildung des Zytoskeletts beteiligt. Diskussion: Autoantikörper gegen Gehirnantigene sind ein physiologisches Phänomen, das unabhängig von dem Vorliegen einer neurologischen Erkrankung besteht. Gehirnareale, die bei Parkinson besonders stark geschädigt werden, werden von dieser humoralen Autoimmunantwort besonders stark erkannt. Eine vorübergehende Permeabilisierung der Blut-Hirn-Schranke durch Infektion oder Trauma könnte den Zutritt der Autoantikörper zum Gehirn erlauben und so autoreaktive Prozesse in Gang setzen und zum Untergang dopaminerger Neuronen führen. Bei den identifizierten Proteinen handelt es sich um grundlegende Bestandteile eukaryotischer Zellen, was die Hypothese eines Art Beseitigungsmechanismus der Autoantikörper und damit die Aufgabe der Aufrechterhaltung der Homöostase darstellen könnte. Bei männlichen PD Patienten wird die 45 kDa Bande signifikant weniger stark von Auto-IgGs erkannt; dieser Mechanismus könnte somit in den männlichen PD-Patienten vermindert sein. Als Folge wäre die Ablagerung von Zelltrümmern im Gehirn vorstellbar, die dann auch langfristig eine Angriffsfläche für Autoimmunprozesse mit dem Verlust dopaminerger Neuronen bieten könnte. N2 - Background: The pathogenic mechanisms of Parkinson’s disease (PD) are not yet fully understood. Particularly the basic cause of the disease remains unclear. In HIV-Infection many patients show neurologic impairments (HIV-associated neurological disorders, HAND), which are similar in clinic symptoms and localization of the affected brain areas to these observed in Parkinson’s disease. Possibly a dysregulation of immunologic responses might play a role as a cause for PD. In this work autoimmune processes in PD- and HAND-patients as well as in healthy controls against different brain homogenates were measured, which are damaged in variable extent during pathogenesis of PD. The autoimmune-signal was quantified and prominent autoantigens were identified. Methods: In this work we established a Western-Blot-based method to detect autoantibodies against brain homogenates. After the optimization with plasma of healthy controls, PD-patients and HIV-infected patients, the technique was used to measure the humoral autoimmunity against different brain areas in a group of 40 PD-patients (mean age 65, 45 % females), and 40 age- and sex-matched controls (mean age 62 years, 50 % female). Different brain areas (of the dorsal motor nucleus of the glossopharyngeal and vagal nerves (dm), substantia nigra (SN), anteromedial temporal mesocortex (MC), high order sensory association areas and prefrontal fields (HC), first order sensory association areas, premotor areas, as well as primary sensory and motor fields (FC)) of post-mortem brains were homogenized, separated by gel electrophoresis and blotted on a nitrocellulose membrane. The membranes were incubated with plasma and bound antibodies were detected immunologically. The signals were analyzed by quality and quantity. With a two-dimensional electrophoresis and following immune staining prominent autoantigens were identified by mass spectroscopy. Results: With the established assay, the humoral autoimmunity against brain tissue can be analyzed semi-quantitatively. In all investigated samples several autoantibodies against different antigens could be proven. The overall IgG-content did not differ significantly between PD-patients and healthy controls, nor between men and women. Female PD-patients show significant stronger signals against dm than male (p = 0.02, Mann-Whitney-U-test), which was recognized significantly stronger than the other brain areas in each patient, independently from sex (p < 0.0001, Friedman-ANOVA). In each brain area 3 bands were recognized stronger than others (45, 40 and 37 kDa), each of them the strongest in dm (p < 0.0001, Friedman-ANOVA). The single analysis of the signal intensities show that PD-patients display significantly less autoreactivity against the 45 kDa-band in SN (p = 0.056), MC (p = 0.0277) and FC (p = 0.0188) than controls. Further analyses show that plasma of male PD-patients detect highly significantly less the 45 kDa-protein in SN (p < 0.0001), MC (p = 0.0042) and FC (p = 0.0088) than controls, whereas there was no difference measurable in female control- and PD-plasma. Another protein at 160 kDa is recognized at significantly different intensities in all brain areas (p < 0.0001, Friedman-ANOVA), whereas the strongest immunoreactivity is shown against FC. Based on the detection of the 45 kDa-band from the SN the odds ratio for the feature PD is 3.38 (CI 1.11 – 10.30). In men the odds ratio is even 53.12 (CI 2.79 - 1012), in female 0.44 (CI 0.09 – 2.09). The sensitivity for the test in the group of men displays 1 (CI 0.84 – 1), the specificity is 4.41 (0.31 – 0.78). The negative predictive values exceed 99.15 % in all investigated groups. The identification of the proteins by mass spectroscopy showed that the 37 – 45 kDa-bands might be isoforms of posttranslational modified forms of GFAP (glial fibrillary acidic protein), a part of neurofilaments in astrocytes. Furthermore, fructose-bisphosphate aldolase A and aspartate aminotransferase (mitochondrial isoform 1 precursor), both in the metabolism of carbon hydrates and glycolysis, have been identified for further 45 kDa-bands. The identified protein with a molecular weight of 160 kDa is probably dihydropyrimidinase-related protein 2, like GFAP involved in the formation of the cytoskeleton. Conclusion: The presence of anti-brain-autoantibodies are a physiological occurrence in human plasma, independent of the presence of neurological disease. Brain areas that are damaged prominently during the pathogenesis of PD are recognized stronger by humoral autoimmunity. A temporal permeabilization of the blood brain barrier through infection or trauma might allow autoantibodies access to the brain and initiate autoreactive processes that lead to the demise of dopaminergic neurons. The identified proteins are basic members of eukaryotic cells. This could suggest the hypothesis of sort of a cleaning mechanism of the antibodies, which might have the function of sustaining homeostasis. Male PD patients showed significantly decreased levels of autoreactive antibodies against the 45 kDa band in SN, MC and FC, which could enhance the accumulation of protein debris due to a missing removal mechanism and in long-distance might be responsible for neurodegenerative processes. KW - Parkinson-Krankheit KW - Autoantikörper KW - Parkinson Disease KW - anti-brain autoantibodies KW - GFAP KW - Gliafaserprotein KW - Anti-Gehirn Autoantikörper Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-149348 ER - TY - JOUR A1 - Busch, Albert A1 - Busch, Martin A1 - Scholz, Claus-Jürgen A1 - Kellersmann, Richard A1 - Otto, Christoph A1 - Chernogubova, Ekaterina A1 - Maegdefessel, Lars A1 - Zernecke, Alma A1 - Lorenz, Udo T1 - Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology JF - International Journal of Molecular Science N2 - Limited comprehension of aneurysm pathology has led to inconclusive results from clinical trials. miRNAs are key regulators of post-translational gene modification and are useful tools in elucidating key features of aneurysm pathogenesis in distinct entities of abdominal and popliteal aneurysms. Here, surgically harvested specimens from 19 abdominal aortic aneurysm (AAA) and 8 popliteal artery aneurysm (PAA) patients were analyzed for miRNA expression and histologically classified regarding extracellular matrix (ECM) remodeling and inflammation. DIANA-based computational target prediction and pathway enrichment analysis verified our results, as well as previous ones. miRNA-362, -19b-1, -194, -769, -21 and -550 were significantly down-regulated in AAA samples depending on degree of inflammation. Similar or inverse regulation was found for miR-769, 19b-1 and miR-550, -21, whereas miR-194 and -362 were unaltered in PAA. In situ hybridization verified higher expression of miR-550 and -21 in PAA compared to AAA and computational analysis for target genes and pathway enrichment affirmed signal transduction, cell-cell-interaction and cell degradation pathways, in line with previous results. Despite the vague role of miRNAs for potential diagnostic and treatment purposes, the number of candidates from tissue signature studies is increasing. Tissue morphology influences subsequent research, yet comparison of distinct entities of aneurysm disease can unravel core pathways. KW - AAA KW - miRNA expression KW - pathway analysis KW - histologic diversity KW - popliteal aneurysm Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-146422 SN - International Journal of Molecular Science VL - 17 IS - 1 ER - TY - JOUR A1 - Brünnert, Daniela A1 - Seupel, Raina A1 - Goyal, Pankaj A1 - Bach, Matthias A1 - Schraud, Heike A1 - Kirner, Stefanie A1 - Köster, Eva A1 - Feineis, Doris A1 - Bargou, Ralf C. A1 - Schlosser, Andreas A1 - Bringmann, Gerhard A1 - Chatterjee, Manik T1 - Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate JF - Pharmaceuticals N2 - The N,C-coupled naphthylisoquinoline alkaloid ancistrocladinium A belongs to a novel class of natural products with potent antiprotozoal activity. Its effects on tumor cells, however, have not yet been explored. We demonstrate the antitumor activity of ancistrocladinium A in multiple myeloma (MM), a yet incurable blood cancer that represents a model disease for adaptation to proteotoxic stress. Viability assays showed a potent apoptosis-inducing effect of ancistrocladinium A in MM cell lines, including those with proteasome inhibitor (PI) resistance, and in primary MM cells, but not in non-malignant blood cells. Concomitant treatment with the PI carfilzomib or the histone deacetylase inhibitor panobinostat strongly enhanced the ancistrocladinium A-induced apoptosis. Mass spectrometry with biotinylated ancistrocladinium A revealed significant enrichment of RNA-splicing-associated proteins. Affected RNA-splicing-associated pathways included genes involved in proteotoxic stress response, such as PSMB5-associated genes and the heat shock proteins HSP90 and HSP70. Furthermore, we found strong induction of ATF4 and the ATM/H2AX pathway, both of which are critically involved in the integrated cellular response following proteotoxic and oxidative stress. Taken together, our data indicate that ancistrocladinium A targets cellular stress regulation in MM and improves the therapeutic response to PIs or overcomes PI resistance, and thus may represent a promising potential therapeutic agent. KW - multiple myeloma KW - ancistrocladinium A KW - naphthylisoquinoline alkaloids KW - proteasome inhibitor resistance KW - RNA splicing KW - cellular stress response KW - proteasome subunit beta type-5 (PSMB5) KW - activating transcription factor 4 (ATF4) KW - ataxia teleagiectasia mutated (ATM) KW - H2A histone family member X (H2AX) Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-362887 SN - 1424-8247 VL - 16 IS - 8 ER - TY - JOUR A1 - Ries, Lena K. A1 - Sander, Bodo A1 - Deol, Kirandeep K. A1 - Letzelter, Marie-Annick A1 - Strieter, Eric Robert A1 - Lorenz, Sonja T1 - Analysis of ubiquitin recognition by the HECT ligase E6AP provides insight into its linkage specificity JF - Journal of Biological Chemistry N2 - Deregulation of the HECT-type ubiquitin ligase E6AP (UBE3A) is implicated in human papilloma virus-induced cervical tumorigenesis and several neurodevelopmental disorders. Yet the structural underpinnings of activity and specificity in this crucial ligase are incompletely understood. Here, we unravel the determinants of ubiquitin recognition by the catalytic domain of E6AP and assign them to particular steps in the catalytic cycle. We identify a functionally critical interface that is specifically required during the initial formation of a thioester-linked intermediate between the C terminus of ubiquitin and the ligase-active site. This interface resembles the one utilized by NEDD4-type enzymes, indicating that it is widely conserved across HECT ligases, independent of their linkage specificities. Moreover, we uncover surface regions in ubiquitin and E6AP, both in the N- and C-terminal portions of the catalytic domain, that are important for the subsequent reaction step of isopeptide bond formation between two ubiquitin molecules. We decipher key elements of linkage specificity, including the C-terminal tail of E6AP and a hydrophilic surface region of ubiquitin in proximity to the acceptor site Lys-48. Intriguingly, mutation of Glu-51, a single residue within this region, permits formation of alternative chain types, thus pointing to a key role of ubiquitin in conferring linkage specificity to E6AP. We speculate that substrate-assisted catalysis, as described previously for certain RING-associated ubiquitin-conjugating enzymes, constitutes a common principle during linkage-specific ubiquitin chain assembly by diverse classes of ubiquitination enzymes, including HECT ligases. KW - ubiquitin KW - ubiquitin ligase KW - ubiquitylation (ubiquitination) KW - post-translational modification KW - enzyme mechanism Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226207 VL - 294 IS - 15 ER - TY - JOUR A1 - Mietrach, Nicole A1 - Schlosser, Andreas A1 - Geibel, Sebastian T1 - An extracellular domain of the EsaA membrane component of the type VIIb secretion system: expression, purification and crystallization JF - Acta Crystallographica Section F N2 - The membrane protein EsaA is a conserved component of the type VIIb secretion system. Limited proteolysis of purified EsaA from Staphylococcus aureus USA300 identified a stable 48 kDa fragment, which was mapped by fingerprint mass spectrometry to an uncharacterized extracellular segment of EsaA. Analysis by circular dichroism spectroscopy showed that this fragment folds into a single stable domain made of mostly α‐helices with a melting point of 34.5°C. Size‐exclusion chromatography combined with multi‐angle light scattering indicated the formation of a dimer of the purified extracellular domain. Octahedral crystals were grown in 0.2 M ammonium citrate tribasic pH 7.0, 16% PEG 3350 using the hanging‐drop vapor‐diffusion method. Diffraction data were analyzed to 4.0 Å resolution, showing that the crystals belonged to the enantiomorphic tetragonal space groups P41212 or P43212, with unit‐cell parameters a = 197.5, b = 197.5, c = 368.3 Å, α = β = γ = 90°. KW - ESAT‐6‐like secretion system KW - ESS KW - type VII secretion system KW - EsaA KW - extracellular domain KW - Staphylococcus aureus USA300 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-213681 VL - 75 IS - 12 ER - TY - JOUR A1 - Sirén, Anna-Leena A1 - Stetter, Christian A1 - Hirschberg, Markus A1 - Nieswandt, Bernhard A1 - Ernestus, Ralf-Ingo A1 - Heckmann, Manfred T1 - An experimental protocol for in vivo imaging of neuronal structural plasticity with 2-photon microscopy in mice JF - Experimental & Translational Stroke Medicine N2 - Introduction Structural plasticity with synapse formation and elimination is a key component of memory capacity and may be critical for functional recovery after brain injury. Here we describe in detail two surgical techniques to create a cranial window in mice and show crucial points in the procedure for long-term repeated in vivo imaging of synaptic structural plasticity in the mouse neocortex. Methods Transgenic Thy1-YFP(H) mice expressing yellow-fluorescent protein (YFP) in layer-5 pyramidal neurons were prepared under anesthesia for in vivo imaging of dendritic spines in the parietal cortex either with an open-skull glass or thinned skull window. After a recovery period of 14 days, imaging sessions of 45–60 min in duration were started under fluothane anesthesia. To reduce respiration-induced movement artifacts, the skull was glued to a stainless steel plate fixed to metal base. The animals were set under a two-photon microscope with multifocal scanhead splitter (TriMScope, LaVision BioTec) and the Ti-sapphire laser was tuned to the optimal excitation wavelength for YFP (890 nm). Images were acquired by using a 20×, 0.95 NA, water-immersion objective (Olympus) in imaging depth of 100–200 μm from the pial surface. Two-dimensional projections of three-dimensional image stacks containing dendritic segments of interest were saved for further analysis. At the end of the last imaging session, the mice were decapitated and the brains removed for histological analysis. Results Repeated in vivo imaging of dendritic spines of the layer-5 pyramidal neurons was successful using both open-skull glass and thinned skull windows. Both window techniques were associated with low phototoxicity after repeated sessions of imaging. Conclusions Repeated imaging of dendritic spines in vivo allows monitoring of long-term structural dynamics of synapses. When carefully controlled for influence of repeated anesthesia and phototoxicity, the method will be suitable to study changes in synaptic structural plasticity after brain injury. KW - 2-photon microscopy KW - Fluorescence KW - In vivo imaging KW - Neurons KW - Cranial window KW - Mouse model Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-96908 UR - http://www.etsmjournal.com/content/5/1/9 ER - TY - JOUR A1 - Segerer, Gabriela A1 - Hadamek, Kerstin A1 - Zundler, Matthias A1 - Fekete, Agnes A1 - Seifried, Annegrit A1 - Mueller, Martin J. A1 - Koentgen, Frank A1 - Gessler, Manfred A1 - Jeanclos, Elisabeth A1 - Gohla, Antje T1 - An essential developmental function for murine phosphoglycolate phosphatase in safeguarding cell proliferation JF - Scientific Reports N2 - Mammalian phosphoglycolate phosphatase (PGP) is thought to target phosphoglycolate, a 2-deoxyribose fragment derived from the repair of oxidative DNA lesions. However, the physiological role of this activity and the biological function of the DNA damage product phosphoglycolate is unknown. We now show that knockin replacement of murine Pgp with its phosphatase-inactive Pgp\(^{D34N}\) mutant is embryonically lethal due to intrauterine growth arrest and developmental delay in midgestation. PGP inactivation attenuated triosephosphate isomerase activity, increased triglyceride levels at the expense of the cellular phosphatidylcholine content, and inhibited cell proliferation. These effects were prevented under hypoxic conditions or by blocking phosphoglycolate release from damaged DNA. Thus, PGP is essential to sustain cell proliferation in the presence of oxygen. Collectively, our findings reveal a previously unknown mechanism coupling a DNA damage repair product to the control of intermediary metabolism and cell proliferation. KW - cell proliferation KW - DNA metabolism KW - lipidomics Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-181094 VL - 6 ER - TY - THES A1 - El Merahbi, Rabih T1 - Adrenergic-induced ERK3 pathway drives lipolysis and suppresses energy dissipation T1 - Der adrenerge induzierte ERK3-Signalweg verstärkt Lipolyse und unterdrückt Energiedissipation N2 - Obesity-induced diabetes affects over 400 million people worldwide. Obesity is a complex metabolic disease and is associated with several co-morbidities, all of which negatively affect the individual’s quality of life. It is commonly considered that obesity is a result of a positive energy misbalance, as increased food intake and lower expenditure eventually lead to the development of this disease. Moreover, the pathology of obesity is attributed to several genetic and epigenetic factors that put an individual at high risk compared to another. Adipose tissue is the main site of the organism’s energy storage. During the time when the nutrients are available in excess, adipocytes acquire triglycerides, which are released during the time of food deprivation in the process of lipolysis (free fatty acids and glycerol released from adipocytes). Uncontrolled lipolysis is the consequent event that contributes to the development of diabetes and paradoxically obesity. To identify the genetic factors aiming for future therapeutic avenues targeting this pathway, we performed a high-throughput screen and identified the Extracellular-regulated kinase 3 (ERK3) as a hit. We demonstrate that β-adrenergic stimulation stabilizes ERK3 leading to the formation of a complex with the co-factor MAP kinase-activated protein kinase 5 (MK5) thereby driving lipolysis. Mechanistically, we identify a downstream target of the ERK3/MK5 pathway, the transcription factor FOXO1, which promotes the expression of the major lipolytic enzyme ATGL. Finally, we provide evidence that targeted deletion of ERK3 in mouse adipocytes inhibits lipolysis, but elevates energy dissipation, promoting lean phenotype and ameliorating diabetes. Moreover, we shed the light on our pharmacological approach in targeting ERK3/MK5 pathways using MK5 specific inhibitor. Already after 1 week of administering the inhibitor, mice showed signs of improvement of their metabolic fitness as showed here by a reduction in induced lipolysis and the elevation in the expression of thermogenic genes. Taken together, our data suggest that targeting the ERK3/MK5 pathway, a previously unrecognized signaling axis in adipose tissue, could be an attractive target for future therapies aiming to combat obesity-induced diabetes. N2 - Adipositas-induzierter Diabetes betrifft weltweit über 400 Millionen Menschen. Adipositas ist eine komplexe Stoffwechselerkrankung und geht mit mehreren Komorbiditäten einher, die sich alle negativ auf die Lebensqualität der Betroffenen auswirken. Es wird generell angenommen, dass Adipositas aus einem positiven Energieungleichgewicht resultiert, da eine erhöhte Nahrungsaufnahme und ein geringerer Verbrauch zu der Ausbildung dieser Krankheit führen. Darüber hinaus ist die Pathologie von Adipositas auf mehrere genetische und epigenetische Faktoren zurückzuführen, wodurch Individuen einem erhöhtem Risiko ausgesetzt sein können. Das Fettgewebe ist der vorwiegende Energiespeicher des Organismus. In Zeiten eines Nährstoffüberschusses speichern Adipozyten Triglyceride, die im Falle eines Nahrungsmangels durch den Prozess der Lipolyse in Form von freien Fettsäuren und Glycerin freigesetzt werden. Unkontrollierte Lipolyse ist ein Folgeereignis, welches zur Entwicklung von Diabetes und paradoxerweise zu Adipositas beiträgt. Um die genetischen Faktoren zu identifizieren, die in Zukunft therapeutische Angriffspunkte darstellen könnten, haben wir ein Hochdurchsatz-Screening durchgeführt und die extrazellulär regulierte Kinase 3 (ERK3) als Treffer identifiziert. Wir zeigen, dass β-adrenerge Stimulation ERK3 stabilisiert, was zur Bildung eines Komplexes mit dem Cofactor MAP-Kinase-aktivierte Proteinkinase 5 (MK5) führt und dadurch die Lipolyse vorantreibt. Mechanistisch identifizieren wir den Transkriptionsfaktor FOXO1, der dem ERK3/MK5-Signalweg nachgeschaltet ist und die Expression des wichtigsten lipolytischen Enzyms ATGL fördert. Darüber hinaus belegen wir, dass die gezielte Deletion von ERK3 in Maus-Adipozyten die Lipolyse hemmt, aber die Energiedissipation erhöht, den mageren Phänotyp fördert und Diabetes lindert. Außerdem nutzen wir einen pharmakologischen Ansatz durch Verwendung eines MK5 spezifischen Inhibitors, um auf den ERK3/MK5-Signalweg abzuzielen. Bereits eine Woche nach Verabreichung des Inhibitors zeigen Mäuse Anzeichen einer verbesserten metabolischen Fitness, die sich durch einer Verringerung der induzierten Lipolyse und eine verstärkte Expression von thermogenen Genen auszeichnet. Zusammenfassend legen unsere Daten nahe, dass der ERK3/MK5-Signalweg, eine zuvor nicht erkannte Signalachse im Fettgewebe, ein attraktiver Ansatzpunkt für zukünftige Therapien zur Bekämpfung von Adipositas-induziertem Diabetes sein könnte. KW - Metabolism KW - Lipolysis KW - Obesity KW - Adrenalin KW - ATGL KW - Foxo1 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-217510 ER - TY - JOUR A1 - Busse, Kathy A1 - Strotmann, Rainer A1 - Strecker, Karl A1 - Wegner, Florian A1 - Devanathan, Vasudharani A1 - Gohla, Antje A1 - Schöneberg, Torsten A1 - Schwarz, Johannes T1 - Adaptive Gene Regulation in the Striatum of RGS9-Deficient Mice JF - PLOS ONE N2 - Background: RGS9-deficient mice show drug-induced dyskinesia but normal locomotor activity under unchallenged conditions. Results: Genes related to Ca2+ signaling and their functions were regulated in RGS9-deficient mice. Conclusion: Changes in Ca2+ signaling that compensate for RGS9 loss-of-function can explain the normal locomotor activity in RGS9-deficient mice under unchallenged conditions. Significance: Identified signaling components may represent novel targets in antidyskinetic therapy. The long splice variant of the regulator of G-protein signaling 9 (RGS9-2) is enriched in striatal medium spiny neurons and dampens dopamine D2 receptor signaling. Lack of RGS9-2 can promote while its overexpression prevents drug-induced dyskinesia. Other animal models of drug-induced dyskinesia rather pointed towards overactivity of dopamine receptor-mediated signaling. To evaluate changes in signaling pathways mRNA expression levels were determined and compared in wild-type and RGS9-deficient mice. Unexpectedly, expression levels of dopamine receptors were unchanged in RGS9-deficient mice, while several genes related to Ca2+ signaling and long-term depression were differentially expressed when compared to wild type animals. Detailed investigations at the protein level revealed hyperphosphorylation of DARPP32 at Thr34 and of ERK1/2 in striata of RGS9-deficient mice. Whole cell patch clamp recordings showed that spontaneous synaptic events are increased (frequency and size) in RGS9-deficient mice while long-term depression is reduced in acute brain slices. These changes are compatible with a Ca2+-induced potentiation of dopamine receptor signaling which may contribute to the drug-induced dyskinesia in RGS9-deficient mice. KW - medium spiny neurons KW - long-term depression KW - dopa-induced dyskinesia KW - adenylyl cyclase KW - Parkinsons disease KW - synaptic plasticity KW - L-3,4-Dihydroxyphenylalanine-induced dyskinesia KW - ampa receptors KW - cholinergic interneurons KW - endocannabinoid release Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117048 VL - 9 IS - 3 ER - TY - JOUR A1 - Li, Cong A1 - Deng, Xiaobing A1 - Xie, Xiaowen A1 - Liu, Ying A1 - Friedmann Angeli, José Pedro A1 - Lai, Luhua T1 - Activation of Glutathione Peroxidase 4 as a Novel Anti-inflammatory Strategy JF - Frontiers in Pharmacology N2 - The anti-oxidative enzyme, glutathione peroxidase 4 (GPX4), helps to promote inflammation resolution by eliminating oxidative species produced by the arachidonic acid (AA) metabolic network. Up-regulating its activity has been proposed as a promising strategy for inflammation intervention. In the present study, we aimed to study the effect of GPX4 activator on the AA metabolic network and inflammation related pathways. Using combined computational and experimental screen, we identified a novel compound that can activate the enzyme activity of GPX4 by more than two folds. We further assessed its potential in a series of cellular assays where GPX4 was demonstrated to play a regulatory role. We are able to show that GPX4 activation suppressed inflammatory conditions such as oxidation of AA and NF-κB pathway activation. We further demonstrated that this GPX4 activator can decrease the intracellular ROS level and suppress ferroptosis. Our study suggests that GPX4 activators can be developed as anti-inflammatory or cyto-protective agent in lipid-peroxidation-mediated diseases. KW - arachidonic acid metabolic network KW - GPX4 KW - enzyme activator KW - allosterism KW - drug discovery KW - anti-inflammatory KW - ferroptosis Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-195985 SN - 1663-9812 VL - 9 IS - 1120 ER -